Dianthus therapeutics highlights recent business achievements and reports q4 and fy 2024 financial results

Phase 2 magic trial of dnth103 in generalized myasthenia gravis (gmg) ongoing; top-line results on track for 2h'25 phase 3 captivate trial of dnth103 in chronic inflammatory demyelinating polyneuropathy (cidp) ongoing; interim responder analysis anticipated in 2h'26 phase 2 momentum trial of dnth103 in multifocal motor neuropathy (mmn) ongoing; top-line results anticipated in 2h'26 $357.0 million of cash provides runway into 2h'27 new york and waltham, mass., march 11, 2025 (globe newswire) -- dianthus therapeutics, inc. (nasdaq: dnth), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the fourth quarter and full year ending december 31, 2024 and provided an update on recent business achievements.
DNTH Ratings Summary
DNTH Quant Ranking